[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"countryName\":\"Iraq\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":706},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,105,0,25,[9,46,75,102,123,146,181,206,227,260,282,304,340,366,397,425,449,477,517,549,577,598,617,641,675],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":21,"enrollmentInfo":22,"targetDuration":4,"studyType":25,"phases":26,"briefSummary":28,"conditions":29,"keywords":31,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100652782","ehbm-based-intervention-for-polycystic-ovarain-syndrome-among-high-female-school-students-100652782",false,"NCT07780214","EHBM-Based Intervention for Polycystic Ovarain Syndrome Among High Female School Students","Efficacy of The Expanded Health Belief Model-Based Intervention in Enhancing Female High School Students' Adherence to Polycystic Ovary Syndrome Health-Protective Behaviors: A Randomized Controlled Trial","EHBM-PCOSHSFS","Inclusion Criteria:\n\n* Be female high school students enrolled in the selected schools during the study period.\n\nBe within the predefined age range specified in the research protocol (for example, 15-18 years).\n\nBe able to read and understand the language used in the intervention and questionnaires.\n\nBe willing to participate in the study. Provide informed consent\u002Fassent, with parental or guardian consent when required.\n\nBe available to participate in all intervention sessions and follow-up assessments.\n\nHave no previously diagnosed PCOS, if the purpose is to evaluate preventive health-protective behaviors among students without an existing diagnosis.\n\nNot be currently participating in another structured lifestyle or PCOS educational intervention.\n\nExclusion Criteria:\n\nParticipants may be excluded if they:\n\n1. Have a previously diagnosed PCOS, if the study is designed to focus on prevention among students without PCOS.\n2. Have a medical condition that prevents or significantly limits physical activity recommended in the intervention.\n3. Have a cognitive, learning, or communication difficulty that prevents them from understanding the intervention or completing the questionnaire.\n4. Are currently participating in another structured lifestyle, weight-management, or PCOS educational program.\n5. Are receiving a treatment or intervention that could substantially influence the study outcomes.\n6. Are absent from a predetermined proportion of intervention sessions (for example, more than 20%-25%).\n7. Fail to complete the baseline assessment or required post-intervention assessment.\n8. Withdraw their consent\u002Fassent at any stage of the study.\n9. Become unavailable because of transfer to another school, prolonged absence, or other circumstances that prevent completion of the",true,"FEMALE","16 Years","18 Years",{"count":23,"type":24},144,"ESTIMATED","INTERVENTIONAL",[27],"NA","This study aims to examine efficacy of The Expanded Health Belief model-based intervention in enhancing female high school students' adherence to polycystic ovary syndrome health-protective behaviors.",[30],"Polycystic Ovarain Syndrome",[32],"Polycystic ovarain syndrome","NOT_YET_RECRUITING","2026-08-19",{"date":36,"type":37},"2026-08-21","ACTUAL",{"date":39,"type":24},"2026-10-01",{"date":41,"type":24},"2027-04-10",{"name":43,"class":44},"Salwan Abed Laftah","OTHER",1,{"id":47,"slug":48,"hasResults":12,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":12,"sex":53,"minAge":21,"maxAge":4,"enrollmentInfo":54,"targetDuration":56,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":74},"100480992","bph-global-registry-100480992","NCT05543200","BPH Global Registry","A Global Registry of Treatments and Outcomes for Benign Prostatic Hyperplasia","Inclusion Criteria:\n\n* Primary diagnosis of BPH with LUTS with prescribed medical treatment or surgical intervention\n\nExclusion Criteria:\n\n* Non-symptomatic BPH\n* No treatment prescribed for BPH","MALE",{"count":55,"type":24},7500,"3 Years","OBSERVATIONAL","Benign prostatic hyperplasia (BPH) is one of the most common performed surgical procedures in urology. Over the past few decades there have been an increasing development of newer surgical treatment options. Additionally, the outcome parameters for BPH treatments have been standardized. While data are available for the initial pivotal studies, post-market release data are lacking. Under the umbrella of uCARE, we have started a prospective, ongoing international registry for recording demographics and outcomes for patients undergoing surgical treatments for BPH.",[60,61],"Benign Prostatic Hyperplasia","Lower Urinary Tract Symptoms",[63],"BPH, Registry, LUTS","RECRUITING","2026-08-11",{"date":67,"type":37},"2026-08-13",{"date":69,"type":37},"2023-03-13",{"date":71,"type":24},"2028-12",{"name":73,"class":44},"Société Internationale d'Urologie",30,{"id":76,"slug":77,"hasResults":12,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":12,"sex":82,"minAge":83,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":25,"phases":87,"briefSummary":88,"conditions":89,"keywords":91,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":45},"100625070","effect-of-cartoon-projection-and-ball-squeezing-on-pain-during-venipuncture-in-children-100625070","NCT07417852","Effect of Cartoon Projection and Ball Squeezing on Pain During Venipuncture in Children","Effect of Immersive Cartoon Projection and Ball Squeezing on Pain During Venipuncture Among Children: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Children aged 4-12 years\n* Requiring venipuncture for routine blood testing\n* Able to watch cartoon video during procedure\n* Parental consent obtained\n\nExclusion Criteria:\n\n* Developmental delay preventing cooperation\n* Severe anxiety disorder\n* Visual impairment\n* Non-English\u002FArabic speaking parents","ALL","2 Years","12 Years",{"count":86,"type":24},120,[27],"The goal of this clinical trial is to learn which distraction method works better to reduce needle pain in children aged 4-12 years during blood draws.\n\nThe main questions it aims to answer are:\n\n* Does watching cartoon videos lower children's pain more than squeezing a stress ball?\n* Which method do parents prefer for their children?\n\n  120 children will be randomly assigned to watch cartoons or squeeze a ball while nurses draw blood. Pain will be measured using a 0-10 pain scale right after the needle.\n\nThis study will help nurses choose the best way to make blood draws less painful for children.",[90],"Venipuncture Pain",[92],"Pediatric pain, venipuncture, distraction, cartoon projection , Ball squeezing","2026-08-05",{"date":95,"type":37},"2026-08-10",{"date":97,"type":24},"2026-09",{"date":99,"type":24},"2027-01",{"name":101,"class":44},"University of Baghdad",{"id":103,"slug":104,"hasResults":12,"nctId":105,"briefTitle":106,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":12,"sex":19,"minAge":21,"maxAge":4,"enrollmentInfo":108,"targetDuration":4,"studyType":25,"phases":110,"briefSummary":111,"conditions":112,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":45},"100650213","clinical-effectiveness-of-combined-arthrocentesis-with-intra-articular-injection-of-meloxicam-in-treatment-of-temporomandibular-joint-internal-derangement-100650213","NCT07743684","Clinical Effectiveness of Combined Arthrocentesis With Intra-articular Injection of Meloxicam in Treatment of Temporomandibular Joint Internal Derangement","Inclusion Criteria:\n\n* Adult patients \\>= 18 years diagnosed clinically with unilateral TMJ internal derangement with or without reduction, based on the Diagnostic Criteria for Temporomandibular Disorders (DC\u002FTMD).\n* Failure of conservative therapy (splint therapy, physiotherapy) for at least 1 month.\n* Willing and able to provide written informed consent.\n\nExclusion Criteria:\n\n* Patients with bilateral TMJ internal derangement.\n* History of TMJ surgery or major trauma on the affected side.\n* Presence of rheumatic disease.\n* Severe degenerative joint disease.\n* Active infection around the TMJ.\n* Known bleeding disorders or patients on anticoagulant therapy.\n* Pregnancy or lactation.\n* Allergy to Meloxicam or its components.\n* Received intra-articular injections (corticosteroids, hyaluronic acid) in the TMJ within at least 3 months.",{"count":109,"type":24},50,[27],"This randomized controlled clinical study is designed to evaluate the clinical effectiveness of combining temporomandibular joint (TMJ) arthrocentesis with a single intra-articular injection of meloxicam in patients suffering from TMJ internal derangement.\n\nTemporomandibular disorders (TMD) are common conditions causing pain, restricted jaw movement, and joint sounds, which can significantly impair patients' quality of life. While conventional treatments include conservative approaches and arthrocentesis alone, finding optimal therapeutic protocols remains crucial for refractory cases.\n\nA total of 50 adult patients diagnosed with unilateral TMJ internal derangement (with or without reduction) who have failed at least one month of conservative therapy will be enrolled and randomly allocated into two equal groups:\n\nStudy Group: Will undergo joint arthrocentesis followed by a single intra-articular injection of meloxicam (15 mg \u002F 1.5 mL).\n\nControl Group: Will undergo joint arthrocentesis alone using Ringer's lactate solution.\n\nPatients will be evaluated across a 12-week postoperative period (at 2, 4, 8, and 12 weeks) to assess primary and secondary outcomes, including pain intensity (measured via a Numerical Rating Scale), maximum mouth opening (inter-incisal distance in millimeters), joint sounds (clicking, popping, or crepitus), and overall patient satisfaction. The findings aim to establish whether adding an intra-articular non-steroidal anti-inflammatory drug (NSAID) enhances the therapeutic benefits of standard TMJ arthrocentesis.",[113],"Temporomandibular Joint Internal Derangement","2026-08-03",{"date":116,"type":37},"2026-08-06",{"date":118,"type":37},"2026-01-01",{"date":120,"type":24},"2027-10",{"name":122,"class":44},"Hussein Mohammed Ridha",{"id":124,"slug":125,"hasResults":12,"nctId":126,"briefTitle":127,"officialTitle":127,"acronym":4,"eligibilityCriteria":128,"healthyVolunteers":12,"sex":82,"minAge":56,"maxAge":129,"enrollmentInfo":130,"targetDuration":4,"studyType":25,"phases":131,"briefSummary":132,"conditions":133,"keywords":135,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":45},"100625069","effect-of-toy-nebulizer-versus-distraction-cards-on-childrens-fear-and-parental-satisfaction-during-nebulization-therapy-a-comparative-study-100625069","NCT07417839","(Effect of Toy Nebulizer Versus Distraction Cards on Children's Fear and Parental Satisfaction During Nebulization Therapy: A Comparative Study","Inclusion Criteria:Children aged 3-6 years receiving nebulization therapy for the first time due to acute respiratory conditions (e.g., asthma or bronchitis).\n\n2\\. Presence of at least one parent (preferably the mother) during the procedure who is capable of evaluation and communication in Arabic or Kurdish.\n\n3\\. Children who are alert and able to cooperate (absence of severe pain or any condition preventing basic communication).\n\n4\\. Voluntary written informed consent obtained from the parents and assent from the child (where applicable).\n\n\\-\n\nExclusion Criteria:Prior history of nebulization therapy (to ensure the fear response is not conditioned by past experiences).\n\n2\\. Children with cognitive, neurological, or developmental disabilities, or severe chronic illnesses (e.g., terminal cancer).\n\n3\\. Parental inability to complete fear or satisfaction questionnaires due to disability or illiteracy.\n\n4\\. Refusal to participate by the child or parent, or the presence of emergency conditions requiring immediate life-saving intervention.\n\n\\-","6 Years",{"count":86,"type":24},[27],"Goal To compare the effectiveness of a toy nebulizer versus distraction cards in reducing fear among children during nebulization therapy while improving parental satisfaction.\n\nAim To evaluate and measure children's fear levels and parents' satisfaction when using toy nebulizers compared to distraction cards in nebulization sessions.\n\nNull hypothesis: (Hᴏ) There is no statistically significant difference in fear levels among children, and parental satisfaction scores in in the toy nebulizer, distraction cards, and control groups.\n\nAlternative hypothesis: (H₁) There is a statistically significant difference in fear levels among children, and parental satisfaction scores in the toy nebulizer, distraction cards, and control groups.",[134],"Fear is a Common Psychological Response Undergoing Medical Procedures,Act From Uncertainty, Anticipation of Pain, Loss of Control, Previous Negative Experiences",[136,137,138],"\"nebulization therapy\"","\"fear\"","\"distraction card\"","2026-07-30",{"date":114,"type":37},{"date":142,"type":37},"2026-04-08",{"date":144,"type":24},"2026-08-01",{"name":101,"class":44},{"id":147,"slug":148,"hasResults":12,"nctId":149,"briefTitle":150,"officialTitle":151,"acronym":152,"eligibilityCriteria":153,"healthyVolunteers":12,"sex":82,"minAge":21,"maxAge":4,"enrollmentInfo":154,"targetDuration":56,"studyType":57,"phases":4,"briefSummary":156,"conditions":157,"keywords":162,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":180},"100327946","icareme-global-registry-multinational-real-world-evidence-in-cardiorenal-and-metabolic-diseases-100327946","NCT03549754","iCaReMe Global Registry: Multinational Real-world Evidence in Cardiorenal and Metabolic Diseases","Real-world Multinational Registry to Determine Management and Quality of Care of Patients With Type 2 Diabetes, Hypertension, Heart Failure and\u002For Chronic Kidney Diseases","iCaReMe","Inclusion Criteria:\n\n1. Being 18 years or older\n2. Having type 2 diabetes, Hypertension, Heart Failure and\u002For chronic kidney disease\n3. Providing written informed consent to participate in the registry\n\nExclusion Criteria:\n\n1. Having a life-threatening co-morbidity with life expectancy below 1 year\n2. Participating in an interventional trial requiring informed consent",{"count":155,"type":24},35000,"To provide real world data on patient characteristics, disease management, healthcare utilization, and outcomes in patients with type 2 diabetes, Hypertension, Heart failure and\u002For Chronic kidney diseases",[158,159,160,161],"Type 2 Diabetes","Hypertension","Chronic Kidney Disease","Heart Failure",[163,158,164,160,165,159,166,167,161,168,169],"Registry","T2DM","CKD","HTN","Adult population","HF","Early cardiorenal complications","2026-07-20",{"date":172,"type":37},"2026-07-22",{"date":174,"type":37},"2018-02-17",{"date":176,"type":24},"2030-12-31",{"name":178,"class":179},"AstraZeneca","INDUSTRY",76,{"id":182,"slug":183,"hasResults":12,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":187,"eligibilityCriteria":188,"healthyVolunteers":18,"sex":82,"minAge":21,"maxAge":189,"enrollmentInfo":190,"targetDuration":4,"studyType":25,"phases":192,"briefSummary":193,"conditions":194,"keywords":196,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":45},"100647860","ehbm-based-intervention-on-collegians-adherence-to-oral-health-behaviors-ehbm--caohb-100647860","NCT07715773","EHBM-Based Intervention on Collegians' Adherence to Oral Health Behaviors (EHBM- CAOHB)","Efficacy of the Expanded Health Belief Model-Based Intervention on Collegians' Adherence to Oral Health Behaviors: A Randomized Controlled Trial","RCT","Inclusion Criteria: The study included\n\n* Male and female students aged 18-25 years.\n* Enrolled as undergraduate students.\n* Willing to participate and provide informed consent.\n\nExclusion Criteria: Students were excluded if they were\n\n* Students with orthodontic appliances or removable prostheses.\n* Recent comprehensive dental treatment.\n* Female students which are pregnant or lactating.\n* Recent contribution in another oral-health behavioral trial or structured oral-health program.","25 Years",{"count":191,"type":24},166,[27],"This study aims to evaluation of collegians adherence to oral health behavers and to examine the efficacy of the Expanded Health Belief Model-based intervention in enhancing oral health behaviors among collegians.",[195],"Oral Health Behavior Change",[197],"Oral Health Behavior","2026-07-19",{"date":200,"type":37},"2026-07-21",{"date":202,"type":37},"2026-03-24",{"date":204,"type":24},"2026-12-01",{"name":101,"class":44},{"id":207,"slug":208,"hasResults":12,"nctId":209,"briefTitle":210,"officialTitle":211,"acronym":212,"eligibilityCriteria":213,"healthyVolunteers":12,"sex":82,"minAge":214,"maxAge":215,"enrollmentInfo":216,"targetDuration":4,"studyType":25,"phases":217,"briefSummary":218,"conditions":219,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":221,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":226,"locationsCount":45},"100647639","3d-printed-reverse-twin-block-for-class-iii-malocclusion-100647639","NCT07710391","3D Printed Reverse Twin Block for Class III Malocclusion","Effectiveness of a Novel 3D Printed Reverse Twin Block in The Management of Maxillary Deficiency of Class III Malocclusion: A Randomized Clinical Trial","3DRTB","Inclusion Criteria:\n\n1. The age group selected is mixed dentition group 8-13 years with residual potential maxillary growth. Patient maturity will be assessed using the Cervical Vertebral Maturation (CVM) method on lateral cephalogram, patients in CS1-CS3 stages will be included to ensure remaining maxillary growth.\n2. Presence of permanent first molar with lower anterior teeth to retain the appliance.\n3. Skeletal\u002Fdental class III tendency with anterior cross bite or reverse overjet: a. Clinically the overjet is equal or less than zero up to -3 mm.\n\n   b. Cephalometric ANB angle equal or less than zero up to -3 degrees and Wits appraisal ≤ -2.\n4. Prescence of unilateral or bilateral posterior crossbite.\n5. Mild to moderate anterior crowding.\n6. Acceptable oral hygiene baseline defined by oral hygiene index (OHI). -\n\nExclusion Criteria:\n\n1. Patients with cleft lip and palate and\u002For craniofacial anomalies.\n2. History of previous orthopedic and\u002For orthodontic treatment.\n3. Presence of uncontrolled systemic disease or medically compromised status.\n4. Uncooperative patient\u002Fparents.","8 Years","13 Years",{"count":74,"type":24},[27],"This RCT aims to evaluate the effectiveness of a novel 3D printed reverse twin block appliance in the management of maxillary deficiency in growing patients having class III malocclusion. The clinical outcomes of this appliance will be compared with the conventional reverse twin block appliance over 6 months treatment period.\n\nprimary objective is evaluating of the effectiveness of 3DRTB in correcting sagittal discrepancies due to maxillary deficiency in class III malocclusion compared to conventional one while secondary objectives are assessment of transverse and vertical jaw relationship produced by 3DRTB compared to CRTB and to evaluate the soft tissue profile of class III patients and to evaluate the maxillary and mandibular incisor inclination, also assessment of patient perception with both appliances by using questionnaire and finally to assess the impact of 3DRTB on oral health compared to CRTB by using oral hygiene index.",[220],"Class III Malocclusion",{"date":200,"type":37},{"date":223,"type":37},"2026-06-10",{"date":225,"type":24},"2027-06-30",{"name":101,"class":44},{"id":228,"slug":229,"hasResults":12,"nctId":230,"briefTitle":231,"officialTitle":232,"acronym":4,"eligibilityCriteria":233,"healthyVolunteers":12,"sex":82,"minAge":21,"maxAge":4,"enrollmentInfo":234,"targetDuration":4,"studyType":25,"phases":236,"briefSummary":237,"conditions":238,"keywords":243,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":252,"lastUpdatePostDateStruct":253,"startDateStruct":255,"completionDateStruct":256,"leadSponsor":258,"locationsCount":45},"100647587","pumpkin-seed-oil-as-a-nutraceutical-for-hemodialysis-patients-100647587","NCT07710183","Pumpkin Seed Oil as a Nutraceutical for Hemodialysis Patients","Potential Role of Pumpkin Seed Oil as a Nutraceutical on the Clinical and Biochemical Outcomes in Hemodialysis Patients","Inclusion Criteria:\n\n* End-stage renal disease (ESRD) on hemodialysis for more than 6 months, on a constant dialysis program.\n* Hemodynamically stable (no recent hospitalization for infections, cardiovascular events, or major surgery within the past 3 months).\n* No active acute infections.\n* Serum albumin ≥ 3.0 g\u002FdL.\n\nExclusion Criteria:\n\n* Regular intake of dietary supplements (e.g., omega-3, antioxidants) for at least one month prior to enrollment.\n* Autoimmune disease, liver disease, cancer, or acquired immunodeficiency syndrome (AIDS).\n* Known sensitivity\u002Fallergy to pumpkin seed oil.\n* Current use of lipid-lowering agents.\n* Diabetes mellitus.\n* Current use of anticoagulants (warfarin, direct oral anticoagulants).\n* Current use of immunosuppressants, corticosteroids, or anti-inflammatory drugs.\n* Pregnant or breastfeeding women.\n* Residual kidney function (urine output \\> 200 mL\u002Fday).",{"count":235,"type":24},100,[27],"Patients with end-stage renal disease (ESRD) on maintenance hemodialysis experience chronic systemic inflammation, oxidative stress, and dyslipidemia, which together drive much of the excess cardiovascular morbidity and mortality seen in this population. Pumpkin seed oil is a nutraceutical rich in polyunsaturated fatty acids, phytosterols,and tocopherols, with documented antioxidant, anti-inflammatory, and antihyperlipidemic properties in preclinical and limited clinical studies. This study investigates the potential role of pumpkin seed oil as a nutraceutical on the clinical and biochemical outcomes of hemodialysis patients. It is a randomized, open-label, prospective interventional study in which daily oral supplementation with pumpkin seed oil (1000 mg once daily) for 3 months is evaluated against usual care. Eighty-five participants will be assigned to either an intervention group (n=45, pumpkin seed oil 1000 mg\u002Fday plus usual care) or a control group (n=40, usual care only). The biochemical outcomes assessed are changes in serum interleukin-6 (IL-6), high-sensitivity C-reactive protein (hsCRP), soluble vascular cell adhesion molecule-1 (sVCAM-1), lipid profile, malondialdehyde (MDA), and superoxide dismutase (SOD) from baseline to the end of the 3-month follow-up period. The study is being conducted at the Hemodialysis Center, Al-Karama Teaching Hospital, Iraq",[239,240,241,242],"End Stage Renal Disease","Chronic Kidney Disease Requiring Chronic Dialysis","Inflammation","Oxidative Stress",[244,245,246,247,248,249,250,251],"Pumpkin seed oil","Hemodialysis","IL-6","hsCRP","sVCAM-1","Malondialdehyde","Superoxide dismutase","Lipid profile","2026-07-13",{"date":254,"type":37},"2026-07-17",{"date":170,"type":24},{"date":257,"type":24},"2027-04-01",{"name":259,"class":44},"Al-Mustansiriyah University",{"id":261,"slug":262,"hasResults":12,"nctId":263,"briefTitle":264,"officialTitle":265,"acronym":266,"eligibilityCriteria":267,"healthyVolunteers":12,"sex":53,"minAge":21,"maxAge":268,"enrollmentInfo":269,"targetDuration":4,"studyType":25,"phases":270,"briefSummary":271,"conditions":272,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":275,"lastUpdatePostDateStruct":276,"startDateStruct":278,"completionDateStruct":279,"leadSponsor":280,"locationsCount":45},"100645651","anabolic-androgenic-steroid-use-among-gym-goers-100645651","NCT07702110","Anabolic-Androgenic Steroid Use Among Gym-Goers","Efficacy of a Transtheoretical Model-Based Intervention on Anabolic-Androgenic Steroid Use Among Gym-Goers: A Randomized Controlled Trial","TTM - AAS","Inclusion Criteria:\n\n● Adult gym members regularly attending the study fitness center(s)\n\n● Male or female, aged 18 years or older\n\n● Current or past-year non-medical use of anabolic-androgenic steroids, or identified as at risk of initiating use\n\n● Willing to participate and provide informed consent\n\n● Able to attend the assigned intervention sessions and complete study assessments\n\nExclusion Criteria:\n\n● Nurses\u002Fparticipants who do not agree to participate in the study\n\n● Use of AAS under current medical supervision\u002Fprescription for a diagnosed condition\n\n● Not available during the study intervention or follow-up period\n\n● Unable to attend the assigned intervention sessions\n\n● Do not complete the required study assessments\n\n● Participated in the pilot study","60 Years",{"count":86,"type":24},[27],"This randomized controlled trial will evaluate the efficacy of a Transtheoretical Model (TTM)-based behavior-change intervention, delivered through stage-matched counseling sessions, on anabolic-androgenic steroid (AAS) use among gym-goers, compared with a control group receiving standard health education. Non-medical AAS use is a growing public health concern in gym and fitness settings and is associated with serious cardiovascular, endocrine, hepatic, and psychiatric harms. Participants will be randomly assigned to either a TTM-based intervention group or a control group. The intervention will tailor counseling content to each participant's stage of change (precontemplation, contemplation, preparation, action, or maintenance) regarding AAS use. The findings of this study will provide evidence on the effectiveness of stage-based behavioral counseling in reducing AAS use and progressing gym-goers toward safer, drug-free training practices.",[273,274],"Anabolic Androgenic Steroid Use","Substance-Related Disorders","2026-07-08",{"date":277,"type":37},"2026-07-14",{"date":275,"type":24},{"date":257,"type":24},{"name":281,"class":44},"Alaa Yousif Ayed Ahmed",{"id":283,"slug":284,"hasResults":12,"nctId":285,"briefTitle":286,"officialTitle":286,"acronym":4,"eligibilityCriteria":287,"healthyVolunteers":18,"sex":82,"minAge":21,"maxAge":288,"enrollmentInfo":289,"targetDuration":4,"studyType":25,"phases":291,"briefSummary":292,"conditions":293,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":295,"lastUpdatePostDateStruct":296,"startDateStruct":298,"completionDateStruct":300,"leadSponsor":302,"locationsCount":45},"100646341","probiotic-vs-zinc-chlorhexidine-znchx-mouthwashes-in-control-halitosis-and-plaque-in-fixed-orthodontic-patients-100646341","NCT07693972","Probiotic Vs Zinc Chlorhexidine Zn\u002FCHX Mouthwashes in Control Halitosis and Plaque in Fixed Orthodontic Patients","Inclusion Criteria:\n\n1. good medical health\n2. no systematic disease\n3. non consuming drugs known to influence salivary flow, halitosis, or oral microbiota\n\nExclusion Criteria:\n\n1. alcohol drinking\n2. smokers, pregnant and lactating womens\n3. allergy or intolerance to corticosteroid treatment, antibiotic, antimicrobial mouth rinses, oral spray or tongue scraper, anti-inflammatory drugs or probiotics.","30 Years",{"count":290,"type":24},60,[27],"This study aims to determine the effect of probiotics and Zn\u002FCHx mouthwashes on plaque accumulation and halitosis in fixed orthodontic patients.",[294],"Halitoses","2026-07-06",{"date":297,"type":37},"2026-07-09",{"date":299,"type":37},"2025-12-31",{"date":301,"type":24},"2026-09-30",{"name":303,"class":44},"Sara M Almshhadany",{"id":305,"slug":306,"hasResults":12,"nctId":307,"briefTitle":308,"officialTitle":309,"acronym":310,"eligibilityCriteria":311,"healthyVolunteers":12,"sex":82,"minAge":312,"maxAge":313,"enrollmentInfo":314,"targetDuration":4,"studyType":25,"phases":315,"briefSummary":316,"conditions":317,"keywords":321,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":295,"lastUpdatePostDateStruct":334,"startDateStruct":336,"completionDateStruct":338,"leadSponsor":339,"locationsCount":45},"100646188","standard--and-micro-dose-rhbmp-2-for-implant-stability-marginal-bone-loss-and-postoperative-sequelae-a-double-blind-randomized-controlled-trial-100646188","NCT07696299","Standard- and Micro-Dose rhBMP-2 for Implant Stability, Marginal Bone Loss, and Postoperative Sequelae: A Double-Blind Randomized Controlled Trial","Comparative Evaluation of Standard- and Micro-Dose Recombinant Human BMP-2 on Implant Stability, Marginal Bone Loss, and Postoperative Sequelae: A Double-Blind Randomized Controlled Trial","SMBMP","Inclusion Criteria:\n\n* Patients aged 20 to 55 years requiring a single dental implant for a single tooth missing in the posterior mandible (strictly limited to one implant per patient to prevent clustering effects and intra-subject correlation).\n\nPatients must be systemically healthy or medically well-controlled, categorized as ASA I or ASA II according to the American Society of Anesthesiologists classification.\n\nSurgical sites must exhibit D2 or D3 bone quality with adequate residual alveolar bone volume (minimum 6 mm width and 10 mm height).\n\nPatients must maintain optimal oral hygiene, suitable for a prosthetically driven implant treatment workflow.\n\nExclusion Criteria:\n\n* Patients presenting with uncontrolled systemic conditions (e.g., unmanaged diabetes mellitus, active osteoporosis).\n\nA history of radiotherapy or chemotherapy in the maxillofacial region. Current heavy smoking habits (\\>10 cigarettes per day). Active and untreated periodontal disease. Pregnancy or lactation.","20 Years","55 Years",{"count":290,"type":24},[27],"This study will compare the effect of standard-dose and micro-dose recombinant human bone morphogenetic protein-2 (rhBMP-2) with a placebo control on dental implant stability in the posterior mandible. Sixty patients requiring a single dental implant will be randomly assigned to one of three groups: standard-dose rhBMP-2, micro-dose rhBMP-2, or sterile saline only. Implant stability will be measured using Resonance Frequency Analysis at baseline, 2 weeks, 4 weeks, and 12 weeks. Marginal bone loss, peri-implant bone density, ectopic bone formation, and postoperative sequelae including swelling, pain, trismus, and soft tissue healing will also be evaluated during follow-up. The aim is to determine whether micro-dose rhBMP-2 can improve implant stability while reducing postoperative complications compared with the standard dose.",[318,319,320],"Tooth Loss \u002F Rehabilitation","Dental Implant","Osseo-Integrated Implants",[322,323,319,324,325,326,327,328,329,330,331,332,333],"rhbmp-2","Recombinant Human Bone Morphogenetic Protein-2","Implant Stability","Micro-dose","Standard-dose","Osstell","Resonance Frequency Analysis","ISQ","Marginal Bone Loss","Peri-implant Bone Density","Posterior Mandible","Randomized Controlled Trial",{"date":335,"type":37},"2026-07-10",{"date":337,"type":24},"2026-12",{"date":71,"type":24},{"name":101,"class":44},{"id":341,"slug":342,"hasResults":12,"nctId":343,"briefTitle":344,"officialTitle":345,"acronym":4,"eligibilityCriteria":346,"healthyVolunteers":12,"sex":82,"minAge":20,"maxAge":347,"enrollmentInfo":348,"targetDuration":4,"studyType":25,"phases":350,"briefSummary":351,"conditions":352,"keywords":355,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":358,"lastUpdatePostDateStruct":359,"startDateStruct":361,"completionDateStruct":363,"leadSponsor":365,"locationsCount":45},"100642864","orthodontic-treatment-outcomes-of-self-ligating-system-compared-to-clear-aligner-system-100642864","NCT07638397","Orthodontic Treatment Outcomes of Self Ligating System Compared to Clear Aligner System","Orthodontic Treatment Outcomes of Self Ligating System Compared to Clear Aligner System : A Randomized Clinical Trial","Inclusion Criteria:\n\n1. Good oral and general health; no systemic conditions affecting bone metabolism or pain perception.\n2. Age range between 16-32 years.\n3. Presence of full permanent dentition except the third molars.\n4. Class I canine and molar relationship moderate crowding in both arches (6-8 mm) requiring fixed orthodontic treatment.\n5. Without previous orthodontic treatment\u002F functional appliances.\n\nExclusion Criteria:\n\n1. Patients will be excluded from enrollment if they have a substantial skeletal discrepancy necessitating orthognathic surgery.\n2. Patient with class Ⅱ , Ⅲ malocclusion.\n3. Patient with external or internal root resorption.\n4. Patients with poor oral hygiene or active periodontal disease.\n5. 90o or more degree of tooth rotation.","32 Years",{"count":349,"type":24},42,[27],"This study is a multi-center, prospective, parallel-group randomized controlled trial designed to compare the orthodontic treatment outcomes of a passive self-ligating bracket system (Damon Ultima) versus a clear aligner system. The primary objective is to evaluate and compare the total orthodontic treatment duration between the two systems in patients with Angle Class I malocclusion and moderate crowding. Secondary objectives include assessing alignment efficiency, patient pain perception at multiple time intervals, dental arch dimension changes, root volume loss percentage, and overall treatment quality using the American Board of Orthodontics Objective Grading System (ABO-OGS).",[353,354],"Angle Class I Maloclussion","Dental Crowding",[356,357],"Damon ultima","clear aligner","2026-07-03",{"date":360,"type":37},"2026-07-07",{"date":362,"type":24},"2026-09-15",{"date":364,"type":24},"2028-08-20",{"name":101,"class":44},{"id":367,"slug":368,"hasResults":12,"nctId":369,"briefTitle":370,"officialTitle":371,"acronym":372,"eligibilityCriteria":373,"healthyVolunteers":12,"sex":19,"minAge":21,"maxAge":4,"enrollmentInfo":374,"targetDuration":4,"studyType":25,"phases":376,"briefSummary":377,"conditions":378,"keywords":386,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":388,"lastUpdatePostDateStruct":389,"startDateStruct":391,"completionDateStruct":393,"leadSponsor":395,"locationsCount":45},"100645034","effect-of-virtual-reality-guided-imagery-on-pain-anxiety-and-fatigue-in-cancer-patients-undergoing-chemotherapy-100645034","NCT07677436","Effect of Virtual Reality-Guided Imagery on Pain, Anxiety, and Fatigue in Cancer Patients Undergoing Chemotherapy","Effect of Virtual Reality Guided Imagery on Pain, Anxiety, and Fatigue in Cancer Patients Undergoing Chemotherapy: A Randomized Controlled Trial","VRGI-Chemo Tri","Inclusion Criteria:\n\n* Female patients aged 18 years or older.\n* Histologically confirmed breast cancer.\n* Stage I, II, or III breast cancer.\n* Underwent surgery as the initial treatment and are scheduled to receive the first cycle of adjuvant chemotherapy, with or without biologic therapy (e.g., AC or TC regimens).\n* Able to read, write, and communicate.\n* Able and willing to use a virtual reality headset.\n* Able to provide written informed consent.\n\nExclusion Criteria:\n\n* Visual or hearing impairment that prevents the use of virtual reality.\n* Serious neurological or psychiatric disorders.\n* Current participation in other non-pharmacological interventions (e.g., meditation or relaxation therapy) that could influence the study outcomes.\n* Previous experience with virtual reality-guided imagery.\n* Use of analgesics, anxiolytics, or other medications during the intervention that may affect the study outcomes.",{"count":375,"type":24},108,[27],"This randomized controlled trial aims to evaluate the effectiveness of virtual reality-guided imagery in reducing pain, anxiety, and fatigue among female breast cancer patients undergoing adjuvant chemotherapy. Participants will be randomly assigned to either an intervention group receiving virtual reality-guided imagery in addition to routine care, or a control group receiving routine care",[379,380,381,382,383,384,385],"Virtual Reality","Guided Imagery","Breast Cancer","Chemotherapy","Pain","Anxiety","Fatigue",[387],"Virtual Reality, Guided Imagery , Breast Cancer, Chemotherapy , Pain, Anxiety , Fatigue","2026-06-27",{"date":390,"type":37},"2026-06-30",{"date":392,"type":24},"2026-07-01",{"date":394,"type":24},"2027-03",{"name":396,"class":44},"Thoalfokar Mohammed Al-Obaidi",{"id":398,"slug":399,"hasResults":12,"nctId":400,"briefTitle":401,"officialTitle":402,"acronym":4,"eligibilityCriteria":403,"healthyVolunteers":18,"sex":82,"minAge":312,"maxAge":404,"enrollmentInfo":405,"targetDuration":4,"studyType":25,"phases":407,"briefSummary":408,"conditions":409,"keywords":411,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":417,"lastUpdatePostDateStruct":418,"startDateStruct":420,"completionDateStruct":421,"leadSponsor":423,"locationsCount":45},"100645340","super-putty-c-prf-hyaluronic-acid-combination-vs-c-prf-in-gingival-phenotype-modification-in-subjects-with-thin-gingival-phenotype-100645340","NCT07682259","Super Putty C-PRF\u002F Hyaluronic Acid Combination vs C-PRF in Gingival Phenotype Modification in Subjects With Thin Gingival Phenotype","Gingival Phenotype Modification Using Super-putty C-PRF\u002FHyaluronic Acid Combination Versus C-PRF Alone in Subjects With Thin Gingival Phenotype: Randomized Clinical Trials","Inclusion Criteria:\n\n1. Systemically healthy male or female adults aged 20 to 40 years.\n2. Non-smoker.\n3. Presence of a clinically thin gingival phenotype (gingival thickness ≤ 1.0 mm) at the targeted surgical sites.\n4. Presence of bilateral homologous teeth (e.g., both maxillary canines, or both mandibular first premolars) exhibiting the same thin gingival phenotype to allow for paired test and control sites within the same oral cavity.\n5. Patients must demonstrate a high standard of oral hygiene, defined as a full-mouth plaque score and full-mouth bleeding score of ≤ 10% following initial cause-related therapy.\n6. Willingness to comply with the 6-month follow-up schedule and provide written informed consent before enrollment.\n\nExclusion Criteria:\n\n1. Any systemic disease or condition known to compromise wound healing or alter immune response (e.g., uncontrolled diabetes mellitus, autoimmune disorders, bleeding dyscrasias).\n2. Current or recent use of medications known to induce gingival enlargement (e.g., phenytoin, cyclosporine, calcium channel blockers) or medications affecting blood coagulation and platelet function (e.g., anticoagulants) within last 10 days of the procedure.\n3. Active periodontitis, defined by probing depths \\> 3 mm or bleeding on probing at the designated experimental sites\n4. Any previous history of mucogingival surgery, soft tissue grafting, or local trauma at the selected test or control sites.\n5. Current tobacco smoking or vaping, due to its well-documented detrimental effects on local angiogenesis and soft tissue grafting outcomes.\n6. Pregnant or lactating females, due to hormonal fluctuations that can temporarily alter the gingival tissue response and capillary permeability.","40 Years",{"count":406,"type":24},20,[27],"Randomized split mouth clinical trials study focused on comparing the efficacy of C-PRF\u002F Hyaluronic acid combination versus C-PRF injection alone in subjects with thin gingival phenotype.",[410],"Thin Gingival Phenotype",[412,413,414,415,416],"periodontics","periodontal phenotype","gingival phenotype","PRF","Hyaluronic acid","2026-06-26",{"date":419,"type":37},"2026-07-02",{"date":392,"type":24},{"date":422,"type":24},"2027-08-01",{"name":424,"class":44},"Sajjad Ahmed Shakir",{"id":426,"slug":427,"hasResults":12,"nctId":428,"briefTitle":429,"officialTitle":430,"acronym":431,"eligibilityCriteria":432,"healthyVolunteers":12,"sex":82,"minAge":4,"maxAge":4,"enrollmentInfo":433,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":435,"conditions":436,"keywords":439,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":440,"lastUpdatePostDateStruct":441,"startDateStruct":443,"completionDateStruct":445,"leadSponsor":447,"locationsCount":448},"100597965","a-multicenter-observational-study-to-understand-the-clinical-characteristics-treatment-patterns-and-access-to-novel-therapies-of-patients-with-diffuse-large-b-cell-lymphoma-in-the-mea-region-100597965","NCT07065344","A Multicenter Observational Study to Understand the Clinical Characteristics, Treatment Patterns and Access to Novel Therapies of Patients With Diffuse Large B-Cell Lymphoma in the MEA Region","A Multicenter Observational Study to Understand the Clinical Characteristics, Treatment Patterns and Access to Novel Therapies of Patients With Diffuse Large B-Cell Lymphoma in the MEA Region A Cross-sectional Multi-center, Observational Study to Describe the Disease Characteristics and Treatment Patterns and Explore Access to Novel Therapies for Diffuse Large B-Cell Lymphoma (DLBCL) Patients for Both Treatment naïve and Relapsed\u002FRefractory Patients in the Middle East & Africa (MEA) Region.","DOMAIN","Inclusion Criteria:\n\n1. Male or female patients aged 18 years or older at diagnosis.\n2. Patients who have confirmed diagnosis of diffuse large B-cell lymphoma (DLBCL) according to the investigator's decision and\u002For histopathological diagnosis.\n3. For Cohort 1: DLBCL patients who are eligible to start treatment\\* according to the investigator's decision.\n4. For Cohort 2: patients who are diagnosed with DLBCL and have failed at least one prior line of therapy.\n5. Patients willing to sign the written informed consent form (ICF) indicating that they understand the purpose of the study and procedures required for participation.\n\nExclusion Criteria:\n\n1. Patients who are not eligible for treatment for any reason, according to the investigator's judgment and decision\n2. Patients with concurrent active malignancies other than DLBCL.\n3. Patients who are actively participating in any other clinical trial.",{"count":434,"type":24},500,"Non-Hodgkin lymphoma (NHL) is the most common hematologic malignancy, with over 80,500 estimated new cases diagnosed in the United States in 20231. Diffuse large B-cell lymphoma (DLBCL) is the most frequent subtype of NHL, accounting for 30%-40% of cases2. DLBCL is an aggressive malignancy with heterogeneous biology and behavior. Disease risk stratification and treatment planning involve various patient and clinical characteristics (e.g., age, stage, and tumor bulk), prognostic indices (e.g., International Prognostic Index (IPI) score), and gene expression profiling. Patients typically present with nodal or extranodal disease, usually exhibiting rapid tumor growth and symptoms that are highly dependent upon the tumor localization.\n\nThe diagnosis and subtyping of DLBCL have significantly advanced, from morphological assessment of tissue slide to numerous ancillary tests, including immunophenotyping performed by immunohistochemistry (IHC), cytogenetics, and detailed molecular testing to classify the disease based on cell of origin (COO). With the advent of novel therapeutic options, molecular subtyping of DLBCL at diagnosis is expected to allow prognostic stratification of patients into distinct subgroups. This stratification could provide a preclinical rationale for therapeutic targeting the involved pathways and paving the application of personalized treatment.\n\nDLBCL is a potentially curable disease with an overall 60-70% chance of achieving durable complete remission (CR) with the currently used standard first-line immunochemotherapy. However, 30-40% of patients are either refractory to first-line treatment or experience relapse and eventually will die of disease progression7. Although high-dose chemotherapy followed by autologous stem cell transplant (ASCT) is the recommended SOC for eligible patients in the second-line setting based on results from the pivotal PARMA study, real-world SOC in this setting remains less clearly defined.\n\nPatients not cured with ASCT or ineligible to ASCT or refractory to salvage chemotherapy may be considered for Chimeric Antigen Receptor (CAR) T cell therapy targeting CD1910. Although ASCT and CAR-T cell therapy offer patients an opportunity for durable remission, many patients may not be eligible for ASCT or CAR-T cell therapy or relapse after these treatments. In the last decade, the investigation of novel antigens, which can be targeted by immunotherapy and identified to eliminate malignant cells regardless of their molecular pathogenesis, has been constantly pursued.\n\nThis study aims to address this need by examining the demographic, clinical characteristics, and treatment patterns and exploring access to novel therapies for diffuse large B-cell lymphoma (DLBCL) patients, both treatment naïve and relapsed\u002Frefractory patients, in the Middle East and Africa (MEA) region.",[437,438],"Hematology","Diffused Large B Cell Lymphoma",[438],"2026-06-17",{"date":442,"type":37},"2026-06-18",{"date":444,"type":37},"2025-07-23",{"date":446,"type":24},"2027-01-31",{"name":178,"class":179},21,{"id":450,"slug":451,"hasResults":12,"nctId":452,"briefTitle":453,"officialTitle":454,"acronym":455,"eligibilityCriteria":456,"healthyVolunteers":18,"sex":82,"minAge":21,"maxAge":404,"enrollmentInfo":457,"targetDuration":4,"studyType":25,"phases":459,"briefSummary":460,"conditions":461,"keywords":465,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":470,"lastUpdatePostDateStruct":471,"startDateStruct":472,"completionDateStruct":473,"leadSponsor":475,"locationsCount":45},"100641094","micro-osteoperforation-versus-photobiomodulation-therapy-for-accelerating-maxillary-canine-retraction-100641094","NCT07658235","Micro-osteoperforation Versus Photobiomodulation Therapy for Accelerating Maxillary Canine Retraction","Micro-osteoperforation Versus Photobiomodulation Therapy for Accelerating Maxillary Canine Retraction: A Three-Arm Parallel Randomized Controlled Clinical Trial.","MOP-PBMT","Inclusion Criteria:\n\n* Age 18 to 40 years at the time of enrollment\n* Systemically healthy with no chronic medical conditions affecting bone metabolism or wound healing\n* Requiring bilateral maxillary first premolar extraction as part of a comprehensive fixed orthodontic treatment plan\n* Class I or mild Class II malocclusion requiring maximum anchorage canine retraction\n* Fully erupted maxillary permanent dentition with no missing teeth other than planned extraction teeth\n* Good oral hygiene (Plaque Index ≤ 1) and healthy periodontal status (probing depth ≤ 3 mm, no bleeding on probing)\n* No previous orthodontic treatment\n* Willing to attend all scheduled appointments and comply with study protocol\n* Able to provide written informed consent\n\nExclusion Criteria:\n\n* Systemic diseases affecting bone metabolism including osteoporosis, osteopenia, diabetes mellitus, thyroid disorders, or autoimmune conditions\n* Current use of medications affecting bone remodeling including corticosteroids, bisphosphonates, non-steroidal anti-inflammatory drugs (NSAIDs), or vitamin D supplements\n* Current or recent smokers (within the past 6 months)\n* Pregnant or breastfeeding women\n* History of head and neck radiation therapy\n* Periodontal disease or active dental infection at the time of enrollment\n* Skeletal Class III malocclusion or severe Class II requiring surgical intervention\n* Previous orthodontic treatment or orthognathic surgery\n* Craniofacial syndromes or cleft lip and palate\n* Photosensitivity disorders or use of photosensitizing medications (relevant to LLLT group)\n* Coagulation disorders or anticoagulant therapy (relevant to MOP group)\n* Uncooperative patients or those unable to maintain adequate oral hygiene throughout treatment\n* Parafunctional habits such as severe bruxism or tongue thrusting'",{"count":458,"type":24},75,[27],"Orthodontic treatment often requires moving the upper canine teeth (the pointed teeth) into the spaces left after removing premolar teeth. This process is usually slow and can take many months, making the total treatment time longer.This study will compare two techniques that may speed up this tooth movement:\n\nMicro-osteoperforation (MOP): A minimally invasive procedure in which a small device is used to create tiny holes in the jawbone near the canine tooth under local anesthesia. These micro-perforations stimulate the bone to remodel faster, which allows the tooth to move more quickly.\n\nPhotobiomodulation therapy (PBMT) \u002F Low-Level Laser Therapy (LLLT): A painless, non-invasive technique that uses a low-power laser light applied to the gum tissue near the canine tooth. The laser energy stimulates cells in the bone and supporting tissues to accelerate tooth movement without any cutting or drilling.\n\nThis trial will randomly assign eligible patients into one of three groups: MOP, LLLT, or a control group receiving standard orthodontic treatment only. Each group will contain 25 participants (75 total). The main goal is to measure and compare how fast the upper canine tooth moves in each group over the first month and until the space is fully closed. The study will also measure the effect of age and sex on the results. The findings will help orthodontists choose the best, fastest, and most comfortable method for each patient to shorten overall treatment time",[462,463,464],"Malocclusion","Orthodontic Tooth Movement","Maxillary Canine Retraction",[466,467,468,469],"Micro-osteoperforation","Photobiomodulation therapy","low-level laser therapy","acceleration of tooth movement","2026-06-16",{"date":442,"type":37},{"date":392,"type":24},{"date":474,"type":24},"2027-05-28",{"name":476,"class":44},"Kufa University",{"id":478,"slug":479,"hasResults":12,"nctId":480,"briefTitle":481,"officialTitle":482,"acronym":483,"eligibilityCriteria":484,"healthyVolunteers":12,"sex":19,"minAge":21,"maxAge":4,"enrollmentInfo":485,"targetDuration":4,"studyType":25,"phases":487,"briefSummary":488,"conditions":489,"keywords":496,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":509,"startDateStruct":511,"completionDateStruct":513,"leadSponsor":515,"locationsCount":45},"100613993","evaluating-an-ai-based-mobile-application-for-chemotherapy-support-in-breast-cancer-patients-100613993","NCT07273812","Evaluating an AI-Based Mobile Application for Chemotherapy Support in Breast Cancer Patients","Evaluating an AI-Based Mobile Application for Chemotherapy Support in Breast Cancer Patients: A Randomized Controlled Trial","AI-ChemoApp","Inclusion Criteria:\n\n* Confirmed diagnosis of breast cancer stages I, II, or III.\n* Patients must be currently scheduled to initiate their first-ever cycle of chemotherapy.\n* Age 18 years or older.\n* Ability to understand and provide informed consent.\n* Possession of a smartphone (Android or iOS) and functional digital literacy, defined as the ability to independently navigate mobile applications, read on-screen text in Arabic, and input daily health data. (for the intervention group).\n* Willingness to comply with study procedures and follow-up schedules.\n* Ability to communicate in Arabic, as the mobile application and chatbot will be developed in Arabic.\n\nExclusion Criteria:\n\n* Patients with Stage IV (Metastatic) breast cancer.\n* Patients receiving concurrent hormonal therapy during the chemotherapy phase, to isolate chemotherapy-induced adverse events.\n\nPatients with cognitive impairment or severe psychiatric disorders that would preclude effective interaction with the mobile application or questionnaire completion.\n\n* Patients receiving palliative care where symptom management is the sole focus and active chemotherapy is not being administered with curative or life prolonging intent.\n* Patients participating in other interventional clinical trials that might confound the outcomes of this study.\n* Patients with severe comorbidities that could significantly impact their ability to participate or bias outcome measures.",{"count":486,"type":24},130,[27],"The goal of this clinical trial is to learn if an Arabic-language mobile application that uses artificial intelligence (AI) can help women with breast cancer during chemotherapy. The app is designed to give personalized support by reminding participants about their medications, teaching them how to manage treatment side effects, and alerting their healthcare team about serious symptoms.\n\nThe main questions this study aims to answer are:\n\n1. Does the AI-based mobile app provide accurate and safe recommendations for the patients?\n2. Does using the AI-based mobile app help lower treatment-related symptoms and side effects compared to usual care?\n3. Does the app help participants take their medications more regularly?\n4. Does it increase participants' understanding and satisfaction with the information they receive about their treatment?\n\nResearchers will compare two groups:\n\nGroup 1: Participants who use the AI-based mobile app plus usual oncology care. Group 2: Participants who receive usual care only.\n\nParticipants will:\n\n1. Use the mobile app daily for 12 weeks while receiving chemotherapy.\n2. Complete short questionnaires about symptoms, medication use, and quality of life at the start and end of the study.\n3. Report any problems or feedback about using the app. The AI app is for support and education only. It does not make treatment decisions. All information from the app will be reviewed by oncologists and pharmacists to ensure participant safety.",[381,490,491,492,493,494,495],"Breast Neoplasm","Chemotherapy-Related Toxicities","Medication Adherence","Quality of Life in Cancer Patients","Accuracy of AI App","Symptom Management",[497,498,499,500,501,502,503,504,505,506,507,508,333],"Artificial Intelligence","Mobile Application","digital health","supportive care","chemotherapy","patient education","Symptom Monitoring","Human-in-the-Loop AI","Breast Cancer Chemotherapy","Oncology","Arabic Language App","Pharmacy Iraq",{"date":510,"type":37},"2026-06-12",{"date":512,"type":37},"2026-06-01",{"date":514,"type":24},"2026-11-06",{"name":516,"class":44},"Dena h. Al-Tameemi",{"id":518,"slug":519,"hasResults":12,"nctId":520,"briefTitle":521,"officialTitle":522,"acronym":523,"eligibilityCriteria":524,"healthyVolunteers":12,"sex":82,"minAge":525,"maxAge":84,"enrollmentInfo":526,"targetDuration":4,"studyType":25,"phases":528,"briefSummary":529,"conditions":530,"keywords":535,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":539,"lastUpdatePostDateStruct":540,"startDateStruct":542,"completionDateStruct":544,"leadSponsor":546,"locationsCount":548},"100625784","pediatric-insulin-plan-calculator-for-t1dm-management-100625784","NCT07427134","Pediatric Insulin Plan Calculator for T1DM Management","Prospective, Parallel-Group Randomised Controlled Trial Evaluating a Flexible Insulin Dose Calculator in Paediatric Type 1 Diabetes Management","FLEXI-T1D","Inclusion Criteria:\n\n* Children and adolescents \\\u003C 12 years\n* Diagnosed with Type 1 Diabetes Mellitus (T1DM)\n* Duration of diagnosis \\> 1 year\n* Using a multiple daily injection (MDI) regimen\n* Practising carbohydrate counting for at least 1 month before enrolment\n\nExclusion Criteria:\n\n* Use of an existing insulin dose calculator (e.g., mobile application or bolus advisor) within the last 3 months\n* Diagnosis of other types of diabetes (e.g., Type 2 diabetes mellitus, monogenic diabetes)\n* Use of insulin regimens other than multiple daily injections (MDI) (e.g., insulin pump therapy)","1 Year",{"count":527,"type":24},440,[27],"This is a multi-centre, prospective, randomized, open-label controlled trial designed to evaluate the effectiveness of a flexible digital insulin dose calculator in children under 12 years of age with Type 1 Diabetes Mellitus (T1DM) managed with multiple daily injections (MDI). Participants will be stratified by continuous glucose monitoring (CGM) use and baseline HbA1c, and randomised to receive either standard care alone or standard care plus the insulin dose calculator tool for 6 months.\n\nThe primary outcome is the change in HbA1c from baseline to 6 months. Secondary outcomes include CGM-derived glycaemic metrics (Time in Range, Time Below Range, Time Above Range, and Coefficient of Variation), total daily insulin dose (units\u002Fkg\u002Fday), healthcare provider contact frequency, and caregiver-reported usability and satisfaction. The study aims to determine whether the use of a structured digital decision-support tool improves glycaemic control and supports safer insulin dosing in paediatric patients with T1DM.",[531,532,533,534],"Type 1 Diabetes Mellitus","Type 1 Diabetes Mellitus (T1DM)","T1DM","T1DM - Type 1 Diabetes Mellitus",[531,536,537,538],"Clinical Decision Support Tool","Digital Health Intervention","Insulin Dose Calculator","2026-06-06",{"date":541,"type":37},"2026-06-09",{"date":543,"type":37},"2026-05-03",{"date":545,"type":24},"2026-12-31",{"name":547,"class":44},"Sultan Qaboos University",2,{"id":550,"slug":551,"hasResults":12,"nctId":552,"briefTitle":553,"officialTitle":554,"acronym":4,"eligibilityCriteria":555,"healthyVolunteers":18,"sex":82,"minAge":556,"maxAge":288,"enrollmentInfo":557,"targetDuration":4,"studyType":25,"phases":559,"briefSummary":560,"conditions":561,"keywords":564,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":570,"lastUpdatePostDateStruct":571,"startDateStruct":572,"completionDateStruct":574,"leadSponsor":575,"locationsCount":576},"100643395","clinical-performance-of-direct-printed-versus-thermoformed-aligners-100643395","NCT07637227","Clinical Performance of Direct-Printed Versus Thermoformed Aligners","Clinical Performance of In-Office Directly Printed Versus Thermoformed Aligners: A Randomized Clinical Trial","Inclusion Criteria:\n\n1. Adult patient with an age range of 15-30 with fully erupted all permanent dentitions excluding third molars, and a willingness to participate in the trial.\n2. Angle Class I non-extraction cases, presented with mild crowding or spacing (\\\u003C5 mm) and dental rotation \\\u003C30° .\n3. Good oral hygiene; no active caries\u002Fperiodontal disease, no history of trauma or root resorption.\n\nExclusion Criteria:\n\n1. Pregnancy, smoking, and systemic conditions affecting bone remodeling.\n2. Subject with poor oral hygiene, using simplified oral hygiene index (OHI-S ≥ 3.1 ) (Greene \\& Vermillion, 1963).\n3. Patient with malposed lower second molars (need orthodontic alignment).\n4. Allergy to materials used (resins, plastics, solvents).\n5. History of trauma, root resorption, and dilacerated roots.\n6. Previous extraction or history of previous orthodontic treatment.","15 Years",{"count":558,"type":24},34,[27],"The goal of this study is to evaluate and compare the clinical effectiveness of in-office directly 3D-printed clear aligners versus conventional multilayered thermoformed aligners.\n\nThe main question it aims to answer is:\n\nDoes the use of in-office direct-printed shape-memory aligners result in superior clinical effectiveness, compared to established multilayer thermoformed aligner systems?\n\nResearchers will compare a Direct-Printed Aligner (DPA) group using Senertek Clear-A V2 resin to a Thermoformed Aligner (TFA) group using Zendura FLX multilayer sheets to see if the additive manufacturing process improves clinical outcomes and patient satisfaction.\n\nParticipants will:\n\n* Undergo initial records including intraoral digital scans, photos, and a panoramic radiograph for treatment planning.\n* Wear their assigned clear aligners (either direct-printed or thermoformed) for at least 22 hours per day, changing them every 7 days.\n* Attend follow-up appointments every 5 weeks.",[562,354,563],"Angle Class I Malocclusion","Tooth Spacing",[565,566,567,568,569,383],"In office aligners","3D printed aligners","Thermoformed Aligners","Tooth movement","Photopolymer Resin","2026-06-05",{"date":541,"type":37},{"date":573,"type":24},"2026-06",{"date":120,"type":24},{"name":101,"class":44},3,{"id":578,"slug":579,"hasResults":12,"nctId":580,"briefTitle":581,"officialTitle":581,"acronym":4,"eligibilityCriteria":582,"healthyVolunteers":12,"sex":82,"minAge":4,"maxAge":4,"enrollmentInfo":583,"targetDuration":585,"studyType":57,"phases":4,"briefSummary":586,"conditions":587,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":589,"lastUpdatePostDateStruct":590,"startDateStruct":591,"completionDateStruct":593,"leadSponsor":595,"locationsCount":597},"100472368","blastic-plasmacytoid-dendritic-cell-neoplasm-bpdcn-international-registry-100472368","NCT05430971","Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry","Inclusion Criteria:\n\n* Diagnosis of BPDCN\n* Signed informed consent form for prospective patients\n\nExclusion Criteria:\n\n\\-",{"count":584,"type":24},200,"5 Years","Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is a very rare hematologic malignancy. Despite recent advances, at present there is no consensus on the optimal treatment of BPDCN. The optimal therapy of disease remains to be determined, and due to the rarity of cases, there is a need for international collaboration to collect data on BPDCN clinical presentations, diagnostics, treatment regimens and outcomes. Therefore, the objectives of this study are: (1) to build a large database of patients with BPDCN, (2) to investigate the characteristics and outcome of the disease with different treatment regimens, (3) to evaluate prognostic factors, and (4) to generate data-based prospective treatment recommendations.",[588],"Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)","2026-06-04",{"date":570,"type":37},{"date":592,"type":37},"2022-07-01",{"date":594,"type":24},"2032-07",{"name":596,"class":44},"Immune Oncology Research Institute",22,{"id":599,"slug":600,"hasResults":12,"nctId":601,"briefTitle":602,"officialTitle":603,"acronym":4,"eligibilityCriteria":604,"healthyVolunteers":12,"sex":82,"minAge":21,"maxAge":268,"enrollmentInfo":605,"targetDuration":4,"studyType":25,"phases":607,"briefSummary":608,"conditions":609,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":611,"lastUpdatePostDateStruct":612,"startDateStruct":613,"completionDateStruct":614,"leadSponsor":616,"locationsCount":45},"100643222","effect-of-medication-adherence-based-digital-intervention-on-fatigue-severity-weight-and-thyroid-hormone-regulation-100643222","NCT07636681","Effect of Medication Adherence-Based Digital Intervention on Fatigue Severity, Weight, and Thyroid Hormone Regulation","Effect of Medication Adherence-Based Digital Intervention on Fatigue Severity, Weight, and Thyroid Hormone Regulation in Patients With Hypothyroidism: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Adults (≥18 years) with primary hypothyroidism.\n* On stable levothyroxine therapy for at least 3 months.\n* Able to read, understand study instructions\n* capable of using basic mobile applications\n* poor medication adherence, clinically significant fatigue, documented weight fluctuations and abnormal thyroid hormone\n\nExclusion Criteria:\n\n* Secondary hypothyroidism or recent thyroidectomy\u002Fradioactive iodine therapy.\n* Pregnancy or breastfeeding woman.\n* Severe psychiatric disorders or cognitive impairment\n* significant visual or hearing deficits\n* Serious comorbidities affecting medication adherence (e.g., chronic disease, renal, or hepatic disease).\n* take dietary supplements or medications that interfere with levothyroxine absorption.",{"count":606,"type":24},80,[27],"1. To evaluate the effect of a medication adherence-based digital intervention on fatigue severity in patients with hypothyroidism.\n2. To assess the effect of a medication adherence-based digital intervention on weight in patients with hypothyroidism.\n3. To investigate the effect of a medication adherence-based digital intervention on thyroid hormone regulation in patients with hypothyroidism.",[610],"Hypothyroidism","2026-06-03",{"date":541,"type":37},{"date":512,"type":24},{"date":615,"type":24},"2026-12-30",{"name":101,"class":44},{"id":618,"slug":619,"hasResults":12,"nctId":620,"briefTitle":621,"officialTitle":622,"acronym":623,"eligibilityCriteria":624,"healthyVolunteers":12,"sex":82,"minAge":4,"maxAge":4,"enrollmentInfo":625,"targetDuration":4,"studyType":25,"phases":627,"briefSummary":628,"conditions":629,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":634,"lastUpdatePostDateStruct":635,"startDateStruct":637,"completionDateStruct":638,"leadSponsor":640,"locationsCount":45},"100638155","development-of-biofunctional-3d-printed-orthodontic-aligners-with-antimicrobial-and-remineralizing-properties-100638155","NCT07603427","Development of Biofunctional 3D-Printed Orthodontic Aligners With Antimicrobial and Remineralizing Properties","Development of Biofunctional 3D Printed Orthodontic Aligners Enriched With Remineralizing and Anti-microbial Agents","3D-BIOALIGN","Inclusion Criteria:\n\n* Extracted human teeth obtained for reasons unrelated to this study (e.g., orthodontic or periodontal indications).\n* Teeth collected after obtaining ethical approval from the Research Ethics Committee.\n* Teeth free from visible cracks, fractures, restorations, or developmental defects.\n\nExclusion Criteria:\n\n* \\- Teeth with caries, restorations, cracks, fractures, or structural defects.\n* Teeth extracted due to pathological conditions affecting enamel or dentin integrity.\n* Teeth with unknown extraction history",{"count":626,"type":24},400,[27],"Clear orthodontic aligners are widely used due to their esthetics and patient comfort; however, prolonged wear may promote biofilm accumulation and enamel demineralization. This laboratory-based (in vitro) study aims to develop and evaluate a novel directly 3D-printed orthodontic aligner resin modified with antimicrobial and remineralizing agents.\n\nThe study will investigate the incorporation of dimethylaminohexadecyl methacrylate (DMAHDM) as an antibacterial agent and amorphous calcium phosphate (ACP) as a remineralizing component into a 3D-printed aligner resin. Modified and unmodified resin specimens will be fabricated and assessed for antimicrobial activity, ion release, and enamel remineralization potential using extracted human teeth.\n\nIn addition, the mechanical and physical properties of the experimental aligner materials, including shape memory behavior, deflection, tensile strength, translucency, and water sorption, will be evaluated to ensure clinical suitability.\n\nThis study does not involve human participants and is conducted entirely in vitro. The findings are expected to contribute to the development of biofunctional orthodontic aligners that actively inhibit bacterial growth and support enamel health without compromising material performance",[630,631,632,633],"Orthodontic Aligner Material","Enamel Demineralization","Dental Biofilm Formation","Clear Aligner Material Properties","2026-05-15",{"date":636,"type":37},"2026-05-22",{"date":512,"type":24},{"date":639,"type":24},"2027-02-01",{"name":101,"class":44},{"id":642,"slug":643,"hasResults":12,"nctId":644,"briefTitle":645,"officialTitle":646,"acronym":4,"eligibilityCriteria":647,"healthyVolunteers":12,"sex":82,"minAge":21,"maxAge":648,"enrollmentInfo":649,"targetDuration":4,"studyType":25,"phases":651,"briefSummary":652,"conditions":653,"keywords":658,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":667,"lastUpdatePostDateStruct":668,"startDateStruct":670,"completionDateStruct":672,"leadSponsor":674,"locationsCount":576},"100640437","effect-of-different-breathing-techniques-on-dyspnea-and-cardiopulmonary-parameters-among-patients-after-open-heart-surgery-100640437","NCT07591987","Effect of Different Breathing Techniques on Dyspnea and Cardiopulmonary Parameters Among Patients After Open Heart Surgery","Effect of Segmental Breathing Versus Active Cycle Breathing Techniques on Dyspnea and Cardiopulmonary Parameters Among Patients After Open Heart Surgery: Randomized Controlled Trial.","Inclusion Criteria:\n\n* Age 18-75 years.\n* Scheduled for elective open-heart surgery.\n* Can understand instructions and perform Segmental breathing and Active cycle breathing techniques.\n* Stable preoperative hemodynamic condition.\n\nExclusion Criteria:\n\n* Emergency cardiac surgeries.\n* Patients with pre-existing severe pulmonary disease (e.g., COPD, asthma, restrictive lung disease, Atelectasis, and Tuberculosis).\n* Neurological disorders affecting breathing effort.\n* Patients with rib fractures, recent thoracic trauma, or contraindications for coughing maneuvers.\n* Inability to provide informed consent (cognitive impairment, language barrier).","75 Years",{"count":650,"type":24},99,[27],"Open heart surgery is often associated with postoperative pulmonary complications, reduced lung expansion, dyspnea, and impaired cardiopulmonary function. Breathing exercises are commonly used after surgery to improve lung ventilation, enhance oxygenation, and support respiratory recovery. However, limited evidence is available comparing the effectiveness of segmental breathing exercises and active cycle breathing technique (ACBT) in patients after open heart surgery.\n\nThis randomized controlled trial will compare the effects of segmental breathing exercises and ACBT on dyspnea and cardiopulmonary parameters in adults undergoing open heart surgery. Participants will be randomly assigned to either the segmental breathing exercise group, the ACBT group, or the standard care group during the postoperative period following extubation.\n\nCardiopulmonary parameters, including oxygen saturation, respiratory rate, heart rate, and blood pressure, as well as dyspnea severity and postoperative pulmonary complications, will be assessed before and after the interventions.\n\nThe findings of this study may help identify the most effective breathing exercise technique for improving respiratory outcomes, reducing postoperative pulmonary complications, and supporting evidence-based postoperative rehabilitation after cardiac surgery.",[654,655,656,657],"Dyspnea","Cardiopulmonary Dysfunction","Postoperative Respiratory Dysfunction","Coronary Artery Disease",[659,660,661,662,663,664,665,654,666],"Open Heart Surgery","Cardiac Surgery","Breathing Exercises","Segmental Breathing Exercises","Active Cycle Breathing Technique","Postoperative Patients","Adult Patients","Cardiopulmonary Parameters","2026-05-14",{"date":669,"type":37},"2026-05-18",{"date":671,"type":37},"2026-01-02",{"date":673,"type":24},"2026-10-10",{"name":101,"class":44},{"id":676,"slug":677,"hasResults":12,"nctId":678,"briefTitle":679,"officialTitle":680,"acronym":681,"eligibilityCriteria":682,"healthyVolunteers":12,"sex":82,"minAge":21,"maxAge":683,"enrollmentInfo":684,"targetDuration":4,"studyType":25,"phases":686,"briefSummary":687,"conditions":688,"keywords":692,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":699,"lastUpdatePostDateStruct":700,"startDateStruct":702,"completionDateStruct":703,"leadSponsor":705,"locationsCount":45},"100628920","combined-mirror-therapy-and-soft-robotic-glove-for-hand-recovery-after-stroke-100628920","NCT07467915","Combined Mirror Therapy and Soft Robotic Glove for Hand Recovery After Stroke","Effect of Combining Mirror Therapy With Soft Robotic Glove on Hand Function Recovery in Post-Stroke Hemiplegic Patients: A Randomized Controlled Trial","MT-SRG","Inclusion Criteria:\n\nAdults aged 18-70 years with first-ever ischemic or hemorrhagic stroke confirmed by imaging (CT or MRI)\n\nModerate upper limb motor impairment (Fugl-Meyer Assessment Upper Extremity \\[FMA-UE\\] score 20-50)\n\nAbility to follow simple instructions (Six-Item Cognitive Impairment Test, 6CIT)\n\nAbility to sit independently for at least 30 minutes\n\nMedically stable and cleared to participate in rehabilitation interventions\n\nWillingness to provide informed consent and adhere to the study protocol\n\nExclusion Criteria:\n\nSevere upper limb spasticity (Modified Ashworth Scale ≥ 3)\n\nCognitive or psychiatric disorders interfering with participation\n\nOther neurological or musculoskeletal conditions affecting upper limb function (e.g., Parkinson's disease, multiple sclerosis, fractures)\n\nPrior exposure to intensive Mirror Therapy or Soft Robotic Gloves\n\nVisual impairment that cannot be corrected with glasses or contact lenses\n\nUncontrolled cardiovascular or other medical conditions that would prevent safe participation","70 Years",{"count":685,"type":24},104,[27],"Post-stroke hemiplegia frequently results in impaired upper limb function, which significantly affects independence and quality of life. Various rehabilitation approaches have been developed to improve motor recovery, including mirror therapy and robotic-assisted training. Mirror therapy uses visual feedback to stimulate neural plasticity and enhance motor recovery, while soft robotic gloves assist repetitive hand movements and facilitate functional training.\n\nThis randomized controlled trial aims to investigate the effect of combining mirror therapy with a soft robotic glove on hand function recovery in patients with post-stroke hemiplegia. Participants will be randomly assigned to different intervention groups receiving mirror therapy, soft robotic glove training, combined therapy, or conventional rehabilitation.\n\nThe primary outcome will assess improvement in upper limb motor function using validated clinical assessment tools. Secondary outcomes will evaluate functional hand performance and activities of daily living. The findings of this study may contribute to improving rehabilitation strategies for stroke survivors and provide evidence for integrating innovative rehabilitation technologies into clinical practice.",[689,690,691],"Stroke","Hemiplegia","Upper Limb Motor Impairment",[693,694,695,696,697,698],"Mirror Therapy","Soft Robotic Glove","Stroke Rehabilitation","Hand Function Recovery","Upper Limb Rehabilitation","Post-Stroke Hemiplegia","2026-05-08",{"date":701,"type":37},"2026-05-13",{"date":142,"type":37},{"date":704,"type":24},"2026-12-17",{"name":101,"class":44},""]